Leukemia

Patients with newly diagnosed, high-risk acute promyelocytic leukemia treated with a combination strategy of ATO plus ATRA and idarubicin experienced improvements in event-free survival.

The FDA approved blinatumomab for patients 1 month or older with CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

Uproleselan plus chemotherapy missed the overall survival end point in the phase 3 trial assessing the combination in patients with relapsed/refractory acute myeloid leukemia.

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

Accelerated approval was granted by the FDA to ponatinib plus chemo for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

An orphan drug designation has been granted by the FDA to ocifisertib as a potential treatment option in acute myeloid leukemia.

It may be feasible to use brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.

A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

Treatment with asciminib for newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase induced statistically significant and clinically meaningful major molecular response benefits compared with standard-of-care TKIs.

SLS009 has been granted fast track status from the FDA to be considered as a potential therapeutic option for relapsed or refractory acute myeloid leukemia.

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.

Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.

At a median 39 months of follow-up, zanubrutinib reduced the risk of disease progression by 32% compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Acalabrutinib, whether as monotherapy or as part of a combination, demonstrated superior progression-free survival outcomes compared to obinutuzumab and chlorambucil.

A new targeted therapy showed promising response rates in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia.

The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.

The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.

Lisocabtagene maraleucel is under consideration as a potential treatment option for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

An analysis of 3 randomized trials showed that acalabrutinib was associated with approximately half the number of cardiac toxicities than with comparator treatments.

Fixed-duration venetoclax plus rituximab continued to outperform bendamustine plus rituximab in the phase 3 MURANO trial.

The FDA has approved bosutinib to treat pediatric patients with Philadelphia chromosome–positive, chronic-phase chronic myelogenous leukemia.

The rate of minimal residual disease-negative complete remission was 34.4% with ponatinib vs 16.7% with imatinib.

Pirtobrutinib was associated with a 19.6-month median progression-free survival in patients with heavily pretreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, describes how nurses used an app imbedded in the electronic medical record to refer patients to the Leukemia & Lymphoma Society.

Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.

Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Individuals with AML who underwent a bone marrow transplant are at an increased risk of developing subsequent neoplasms, and other chronic health conditions.